AbCellera Biologics (ABCL) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Truist Securities | Maintained | Buy | $30.00 from $12.00 | Aug 11, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $12.00 from $11.00 | Aug 6, 2026 |
| Stifel | Maintained | Buy | $9.00 from $8.00 | Aug 6, 2026 |
| Benchmark | Upgraded | Hold → Buy | $11.00 | Jul 7, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $7.00 | May 5, 2026 |
| Jones Trading | Initiated Coverage | Buy | $11.00 | Apr 10, 2026 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $4.00 | Nov 7, 2025 |
| Stifel | Maintained | Buy | $7.00 from $8.00 | Aug 8, 2025 |
| Keybanc | Maintained | Overweight | $10.00 from $5.00 | Jul 14, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $5.00 | Jul 7, 2025 |
| Truist Securities | Maintained | Buy | $10.00 from $28.00 | May 16, 2025 |
| Keybanc | Maintained | Overweight | $5.00 from $4.00 | Apr 16, 2025 |
| Benchmark | Maintained | Hold | — | Mar 3, 2025 |
| Stifel | Maintained | Buy | $10.00 from $12.00 | Feb 28, 2025 |
| Keybanc | Maintained | Overweight | $4.00 from $5.00 | Jan 8, 2025 |
| Stifel | Maintained | Buy | $12.00 from $14.00 | Nov 5, 2024 |
| Benchmark | Maintained | Hold | — | Nov 5, 2024 |
| Benchmark | Downgraded | Buy → Hold | — | Aug 20, 2024 |
| Keybanc | Maintained | Overweight | $5.00 from $7.00 | Jul 11, 2024 |
| Keybanc | Maintained | Overweight | $7.00 from $8.00 | May 8, 2024 |
Frequently asked questions
What is the price target for ABCL stock?
The average 12-month analyst price target for AbCellera Biologics (ABCL) is $15.50, with a high estimate of $30.00 and a low of $9.00, across 4 analysts.
Is ABCL a buy, sell, or hold?
Analysts covering AbCellera Biologics currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ABCL?
The average price target of $15.50 implies 35.02% upside from the last price of $11.48.
What is the latest analyst rating on ABCL?
On Aug 11, 2026, Truist Securities maintained AbCellera Biologics at Buy with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.